Implante transcateter de bioprótese valvular pulmonar: revisão sistemática da literatura

• Autor(a) principal: Botrel, Tobias Engel Ayer
• Data de Publicação: 2013
• Outros Autores: Clark, Otávio Augusto C., Queiroga, Marcelo C., Rossi Filho, Raul I., Pilla, Carlo B., Arrieta, Raul S., Cristovão, Salvador [UNIFESP], Silva, Célia C. [UNIFESP], Esteves, Cesar A., Oliveira, Edmundo Clarindo, Simões, Luiz Carlos, Chamié, Francisco, Neves, Juliana, Max, Roberto, Pedra, Carlos A. C.
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Institucional da UNIFESP
• dARK ID: ark:/48912/0013000015518
• DOI: 10.1590/S2179-83972013000200015
• Texto Completo: http://dx.doi.org/10.1590/S2179-83972013000200015; http://repositorio.unifesp.br/handle/11600/7756
• topic: Pulmonary valve; Cardiac catheterization; Heart valve prosthesis; Prosthesis and implants; Review; Valva pulmonar; Cateterismo cardíaco; Próteses valvulares cardíacas; Próteses e implantes; Revisão

Surgical repair of some complex congenital heart diseases involves reconstruction of the right ventricular outflow tract using homografts, bioprostheses, bovine jugular grafts or other valved conduits between the right ventricle and the main pulmonary artery. Although these surgical procedures may be performed with low mortality rates, the life span of these implanted valves or conduits is usually short (< 10 years) due to either degeneration and/or calcification. Variable degrees of pulmonary stenosis, often associated with pulmonary insufficiency, are consequences of conduit degeneration. In 2000, Bonhoeffer et al. were the first to report the transcatheter pulmonary valve implantation (TPVI) of a bioprosthetic pulmonary valve later named Melody® valve (Medtronic, Minneapolis, USA). The technique was initially developed to limit the need for multiple surgical procedures, and, ultimately, to work as a surrogate of a new surgical valve replacement. Subsequent clinical studies in Europe and the United States confirmed the safety and efficacy of this technique in a larger number of patients. Since the National Sanitary Surveillance Agency (Agência Nacional de Vigilância Sanitária - Anvisa) granted approval for clinical use of the Melody® transcatheter pulmonary biological valve in February 2103, we deemed that a judicious assessment of this new technology was timely and necessary before the widespread use in our country. The objective of this study was to perform a systematic literature review on the use of TPVI in patients with dysfunctional homografts, valved conduits and bioprostheses implanted surgically in the right ventricular outflow tract.